EU recommends marketing approval for Evusheld to treat COVID-19
Recommendation based on Tackle phase-III treatment data showing reduced risk of severe COVID-19 or death
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Evusheld
US plans to move COVID vaccines and treatments to private markets in 2023
President Joe Biden's administration expects to run out of federal funding for buying and distributing COVID-19 vaccines by…
AstraZeneca boosts COVID portfolio with RQ Bio deal
The deal gives AstraZeneca the rights to develop and sell six antibodies, none of which has been tested in humans so far
EU approves Evusheld for preventing COVID-19
Evusheld retains neutralising activity against the Omicron BA.2 subvariant
Evusheld recommended for approval in EU for prevention of COVID-19
Recommendation based on phase-III Provent trial showing a significant reduction in the risk of developing symptomatic COVID-19,…
We remain optimistic that Evusheld will retain its efficacy against Omicron variant
Dr Anil Kukreja, Vice President, Medical Affairs and Regulatory, AstraZeneca India, tells Akanki Sharma about Evusheld, which was…
Israel to offer AstraZeneca’s Evusheld to immunocompromised people
Evusheld has been approved by the US FDA and has proven to be 83 per cent effective in preventing serious illness and death from…
AstraZeneca welcomes US government’s announcement to purchase additional 500,000 doses of…
Evusheld has Emergency Use Authorisation (EUA) for pre-exposure prophylaxis (prevention) of COVID-19
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in…
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
US FDA grants EUA to AstraZeneca’s Evusheld in US for pre-exposure prophylaxis of COVID-19
Phase-III data showed at least six months of protection with one dose in high-risk participant population